Royalty Pharma
RPRX
379 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 142 increasing their positions, 127 reducing their positions, and 55 closing their positions.
222% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $4.19M
25% more capital inflows, than outflows
Capital inflows: $743M | Capital outflows: $594M
12% more repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 127
9% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 55
0% more funds holding
Funds holding: 378 → 379 (+1)
0.09% more ownership
Funds ownership: 70% → 70.09% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Swedbank
Stockholm,
Sweden
|
+$70.2M |
| 2 |
BlackRock
New York
|
+$50.2M |
| 3 |
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$45.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$29.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$159M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$81.4M |
| 3 |
Millennium Management
New York
|
-$64.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.8M |
| 5 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$14.5M |
RPRX Hedge Fund Activity: Q2 2024 in Review
379 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 12% from $9.49B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new RPRX positions and 55 closed out — a net gain of 5 holders — while 142 added to existing stakes and 127 trimmed.
The largest buyer was Swedbank, adding an estimated $70.2M. The largest seller was Fidelity Investments, cutting an estimated $159M.
- 379 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, up from 378 in Q1 2024.
- Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 12% quarter-over-quarter.
- 60 funds opened new Royalty Pharma positions in Q2 2024 and 55 closed out, a net change of +5 holders.
- The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $70.2M added.
- The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.
Based on aggregated 13F filings for Q2 2024.